Novo NordiskNVO
Novo Nordisk on podcasts: where it advertises, what it's offering listeners, and what hosts say about it when they're not being paid.
Sponsorships
No ad reads on tracked podcasts in the last 30 days. Hosts are talking about it anyway — see the earned side.
What hosts are saying
Most mentioned on
In their words
“Nordisk, which recently rebranded to Novo, they traded, you know, from a share price perspective somewhat in lock step. we have just seen steadily quarter after quarter Eli Liy's financial performance has just broadly outpaced Novos. Novo kind of famously also spent billions, but they bought uh a few manufacturing sites, but they've had a lot of issues with integration.”
The host compares Novo unfavorably to Eli Lilly, noting weaker financial performance, execution issues, and difficulty gaining market share in the GLP-1 space.
▶ Hear it“'either, you know, Novo or Lilly or the NIH. This is a This is a fundable and and thoughtful study.'”
Mentioned as a potential funder of a proposed GLP-1 agonist cancer study with no evaluative language.
▶ Hear it“why did Nova Nordisk make a deal with them earlier this year? They could have maybe bludgeoned him and hers in courts over the next five years trying to figure out this patent lawsuit. Or they could have said, "Hey, you're actually a pretty big distributor."”
Mentioned in context of a business partnership deal with Hims & Hers regarding distribution of GLP-1 medications.
▶ Hear itThe full picture
A weekly email with where each one advertised and what hosts said about them. Free.